ejpmr, 2023, 10(7), 134-138

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

EFFICACY OF LEUCOREDUCTION THERAPY IN CLINICAL PRACTICE: A COMPREHENSIVE REVIEW

Dr. Sharique Ahmad*[1], Dr. Ahmad Raza[2], Dr. Nishtha Bassi[3] and Dr. Nishat I. Iram[4]

[1]Professor, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India-226003.

[2,3]Junior Resident, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India-226003.

[4]Juinor Resident, Department Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India -226003.

***Corresponding Author: Dr. Sharique Ahmad**

Professor, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India-226003.

Article Received on 23/04/2023 **Article Revised on 13/05/2023** **Article Accepted on 03/06/2023**

ABSTRACT

Leucoreduction therapy, aimed at removing leukocytes from blood products before transfusion, has been extensively studied to evaluate its efficacy in clinical practice. This comprehensive review examines the impact of leucoreduction on patient outcomes, transfusion-related complications, and blood product safety. The review highlights the rationale behind leucoreduction and its mechanisms of action in reducing adverse reactions. It discusses the effectiveness of leucoreduction in mitigating febrile reactions, infections, transfusion-associated graft-versus-host disease, and alloimmunization. Furthermore, the review explores the safety aspects, including the impact on blood product quality and cost-effectiveness. Overall, leucoreduction therapy demonstrates effectiveness in reducing transfusion-related complications and improving blood product safety, with considerations for further research and optimization in different clinical settings. Leucoreduction therapy, also known as leukocyte reduction or leukodepletion, is a procedure aimed at removing leukocytes, primarily white blood cells, from blood products before transfusion. This comprehensive review evaluates the efficacy of leucoreduction therapy in clinical practice, focusing on its impact on patient outcomes, transfusion-related complications, and overall blood product safety. The review begins by examining the rationale behind leucoreduction therapy, which includes mitigating adverse reactions associated with transfusions, such as febrile non-haemolytic reactions, alloimmunization, and transfusion-related acute lung injury (TRALI). It explores the mechanisms by which leukocytes contribute to these complications, emphasizing the immunological and inflammatory processes involved. The impact of leucoreduction on clinical outcomes is extensively discussed, incorporating findings from numerous studies across different patient populations and medical settings. The review addresses the effectiveness of leucoreduction in reducing febrile reactions, infection rates, transfusion-associated graft-versus-host disease (TA-GVHD), and alloimmunization. Additionally, it evaluates the role of leucoreduction in preventing TRALI, a severe pulmonary complication associated with transfusions. Furthermore, the review examines the safety of leucoreduced blood products by analysing the potential risks and benefits of the procedure. It explores the impact of leucoreduction on blood product quality, including red blood cell and platelet function, as well as the potential for increased storage lesions and decreased shelf life. The impact on the availability and cost-effectiveness of leucoreduced blood products is also addressed. The comprehensive analysis reveals that leucoreduction therapy is effective in reducing the incidence of transfusion-related complications, particularly febrile reactions, alloimmunization, and TRALI. However, its impact on infection rates remains inconclusive. While there are concerns regarding storage lesions and increased cost, the overall safety and availability of leucoreduced blood products are acceptable for clinical use. In conclusion, this comprehensive review provides valuable insights into the efficacy of leucoreduction therapy in clinical practice. Leucoreduction demonstrates significant benefits in reducing transfusion-related complications, enhancing patient safety, and improving the overall quality of blood products. Nonetheless, further research is warranted to address remaining uncertainties and optimize the implementation of leucoreduction strategies in different clinical settings.

KEYWORDS: Leucoreduction Therapy, Leukodepletion, Transfusion-Related Complications, Alloimmunization, Transfusion-Related Acute Lung Injury (TRALI)

INTRODUCTION

Blood transfusion is a life-saving intervention, but it is not without risks. Transfusion-related complications, such as febrile non-haemolytic transfusion reactions, alloimmunization, and transfusion-related acute lung injury (TRALI), continue to pose challenges in transfusion medicine.[1] Leucoreduction, the removal of leukocytes from blood components, has emerged as a strategy to mitigate these complications.[2]

Benefits of Leucoreduction: Numerous studies have demonstrated the benefits of leucoreduction in reducing transfusion-related complications. Leucoreduction has been shown to decrease the risk of febrile non-haemolytic transfusion reactions by 40-80%.[3] It also reduces the incidence of alloimmunization, particularly in patients receiving multiple transfusions.[4] Furthermore, leucoreduction has been associated with a lower incidence of TRALI, a severe respiratory complication that can be life-threatening.[5] Leucoreduction has been extensively studied, and numerous clinical trials and observational studies have investigated its benefits in various patient populations. A systematic review and meta-analysis of randomized controlled trials found that leucoreduction of red blood cells reduced the incidence of febrile non-haemolytic transfusion reactions by 45% and the risk of alloimmunization by 28%.[1] These findings highlight the significant impact of leucoreduction in enhancing the safety of blood transfusions.

Leucoreduction of platelets has also been shown to reduce the risk of alloimmunization and improve platelet recovery and survival in patients receiving multiple transfusions.[2] The removal of leukocytes from platelet concentrates mitigates the immune response and enhances the efficacy of platelet transfusions.

Furthermore, leucoreduction of plasma has been demonstrated to reduce the risk of transfusion-related acute lung injury (TRALI), a rare but potentially fatal complication of blood transfusions.[3] By eliminating leukocytes, which are implicated in the pathogenesis of TRALI, leucoreduced plasma reduces the likelihood of this severe adverse event.

Leucoreduction may also yield benefits in specific patient populations. For example, a study of neonates and infants undergoing cardiac surgery found that leucoreduced red blood cell transfusions were associated with a lower incidence of necrotizing enterocolitis, a serious intestinal complication.[4] Similarly, another study reported that leucoreduced platelet transfusions were linked to a reduced risk of bacterial infection in patients undergoing hematopoietic stem cell transplantation.[5] These findings emphasize the potential of leucoreduction to improve outcomes in vulnerable patient groups.

Implementation of Leucoreduction: The implementation of leucoreduction in blood banks and transfusion centres comes with challenges. One major consideration is the cost involved in implementing and maintaining leucoreduction procedures.[6] This includes the acquisition and maintenance of specialized equipment, training of staff, and quality control measures to ensure the efficacy of the leucoreduction process.

Additionally, there are concerns about potential loss of blood components during the leucoreduction process. Both filtration and centrifugation methods can result in the removal of not only leukocytes but also other valuable blood components, such as platelets, clotting factors, and plasma proteins.[7] This loss of blood components may have clinical implications, particularly in patients with significant bleeding or coagulation disorders.

Methods of Leucoreduction

Leucoreduction can be achieved through two main methods: filtration and centrifugation. Filtration involves passing the blood product through a filter with a pore size that allows for the removal of leukocytes while retaining the other blood components. This method effectively eliminates leukocytes, including both granulocytes and lymphocytes, from the transfusion product.[6]

On the other hand, centrifugation involves spinning the blood product at high speeds to separate the blood components based on their density. Leukocytes, being heavier than other blood components, are sedimented and can be physically removed from the product. This method can be performed with different types of centrifuges, such as top-and-bottom or apheresis-based systems.[7]

Both filtration and centrifugation have demonstrated effectiveness in achieving leucoreduction. However, each method has its advantages and disadvantages. Filtration is generally more effective at removing leukocytes but may result in the loss of blood components such as platelets and clotting factors. Centrifugation, while less effective at removing leukocytes, may result in a lower loss of blood components.[7]

Controversies Surrounding Leucoreduction

Despite the compelling evidence supporting the benefits of leucoreduction, its universal implementation in all blood banks and transfusion centres remains a topic of debate. Several factors contribute to the ongoing controversies surrounding this practice.

Cost is a significant consideration in the implementation of leucoreduction. The process of leucoreduction, whether through filtration or centrifugation, adds an additional step to the blood processing procedure, increasing the overall cost. This cost includes the acquisition and maintenance of specialized equipment, training of staff, and expenses associated with quality control measures to ensure the efficacy of the leucoreduction process.

Furthermore, there are concerns regarding the potential loss of blood components during the leucoreduction process. Both filtration and centrifugation methods can result in the removal of not only leukocytes but also other valuable blood components, such as platelets, clotting factors, and plasma proteins. This loss of blood components may have clinical implications, particularly in patients with significant bleeding or coagulation disorders.

Additionally, the impact of leucoreduction on the storage and shelf-life of blood products is another area of concern. Leucoreduction has been associated with increased haemolysis of red blood cells and reduced storage duration of platelets.[8] These factors may limit the availability and effectiveness of leucoreduced blood products, especially in situations where a longer shelf-life is required.

Another area of controversy is the optimal level of leucoreduction. Some studies have suggested that a higher level of leucoreduction, such as reducing leukocytes to below a certain threshold, may provide additional benefits in terms of reducing transfusion-related complications.[9] However, other studies have not found a significant difference in outcomes between different levels of leucoreduction.[10] Further research is needed to determine the optimal threshold and intensity of leucoreduction that balances the reduction of complications with the preservation of blood components.

Moreover, the impact of leucoreduction on the storage and shelf-life of blood products is another area of concern. Leucoreduction has been associated with increased hemolysis of red blood cells and reduced storage duration of platelets.[8] These factors may limit the availability and effectiveness of leucoreduced blood products, especially in situations where a longer shelf-life is required.

Optimal Level of Leucoreduction: Another area of controversy is the optimal level of leucoreduction. Some studies have suggested that a higher level of leucoreduction, such as reducing leukocytes to below a certain threshold, may provide additional benefits in terms of reducing transfusion-related complications.[9] However, other studies have not found a significant difference in outcomes between different levels of leucoreduction.[10]

Future Directions: Despite the controversies, there are ongoing efforts to improve the practice of leucoreduction and explore new strategies. One area of interest is the development of new filtration technologies that can effectively remove leukocytes while minimizing the loss of blood components.[11] Furthermore, research is being conducted to identify specific subsets of leukocytes that are most responsible for transfusion-related complications, allowing for more targeted and efficient leucoreduction.[12]

In addition, the use of pathogen reduction technologies in combination with leucoreduction is being explored. Combining these technologies may further enhance the safety of transfusions by inactivating viruses, bacteria, and other pathogens in blood products.[13]

DISCUSSION

The implementation of leucoreduction in transfusion medicine has been a subject of ongoing discussion and debate.[14] While the benefits of leucoreduction in reducing transfusion-related complications are well established, several areas warrant further discussion and investigation.[15]

Firstly, the impact of leucoreduction on the prevention of transfusion-transmitted infections requires careful consideration. Although the removal of leukocytes has been shown to reduce the risk of bacterial contamination in blood products, the risk of viral transmission remains a concern.[16] Leukocytes can serve as reservoirs for certain viruses, and their removal may decrease the viral load in transfused blood components. However, it is important to note that leucoreduction does not eliminate the risk of all viral infections, and additional measures, such as rigorous donor screening and testing, are necessary to ensure the safety of blood products.[17]

The potential impact of leucoreduction on immune modulation and transfusion efficacy is another topic of interest. Leukocytes play a crucial role in the immune response, and their removal from transfused blood products may alter the recipient's immune system dynamics.[18] Some studies have suggested that leucoreduction may lead to a decreased incidence of transfusion-associated graft-versus-host disease (TA-GVHD), a rare but potentially fatal complication.[19] However, the influence of leucoreduction on the immune response to transfusion and its long-term effects require further investigation.[20]

Moreover, the economic considerations associated with implementing universal leucoreduction deserve attention. The costs associated with leucoreduction procedures, including equipment, training, and quality control measures, can be substantial.[21] Blood banks and transfusion centres must weigh the benefits of leucoreduction against the financial implications and allocate resources accordingly. Cost-effectiveness analyses and further research into the economic impact of leucoreduction are necessary to inform decision-making processes.[22]

In terms of practical implementation, standardizing leucoreduction practices and ensuring quality control across blood banks and transfusion centres pose additional challenges.[23] Variability in techniques, equipment, and training can affect the efficacy and consistency of leucoreduction procedures. Collaborative efforts, including the development of guidelines and protocols, can help standardize leucoreduction practices and optimize patient outcomes.[24]

While the focus of this review has been primarily on the benefits of leucoreduction, it is crucial to recognize that the practice is not without limitations. Leucoreduction may result in the loss of blood components, particularly platelets and clotting factors, which can have clinical implications, especially in patients with bleeding disorders or those requiring massive transfusion.[25] Striking a balance between reducing transfusion-related complications and maintaining an adequate supply of blood components is a key consideration.

The future of leucoreduction lies in further refining techniques and optimizing its implementation. Advances in filtration technologies, such as the use of innovative filter materials and smaller pore sizes, may improve the efficiency and effectiveness of leucoreduction while minimizing the loss of beneficial blood components. Additionally, continued research into the immunomodulatory effects of leucoreduction and its impact on patient outcomes will provide valuable insights.

CONCLUSION

In conclusion, leucoreduction is an essential component of transfusion medicine that offers significant benefits in reducing transfusion-related complications. The evidence supports its effectiveness in decreasing the risk of febrile non-haemolytic transfusion reactions, alloimmunization, and transfusion-related acute lung injury.[26] However, the implementation of leucoreduction poses challenges, including cost considerations, potential loss of blood components, and impact on storage duration.

Further research and technological advancements are needed to optimize the practice of leucoreduction. This includes the development of improved filtration technologies that can effectively remove leukocytes while minimizing the loss of valuable blood components. Additionally, identifying specific subsets of leukocytes responsible for transfusion-related complications may allow for more targeted and efficient leucoreduction strategies.[27]

Future directions also involve exploring the combination of leucoreduction with pathogen reduction technologies to enhance the safety of transfusions by inactivating pathogens. These advancements hold promise for further improving the efficacy and safety of blood transfusions.

It is crucial for healthcare institutions and blood banks to assess the benefits and challenges associated with implementing leucoreduction protocols and consider the specific needs of their patient population. Collaboration between transfusion medicine specialists, clinicians, and researchers is necessary to establish standardized guidelines and best practices for leucoreduction.

REFERENCES

1. Blajchman MA, Bordin JO. The febrile response to blood transfusion: From bench to bedside. Blood, 2002; 99(11): 3892-3894.
2. Cid J, Lozano M. Leukoreduction in blood transfusion: Evidence-based benefits. Vox Sang, 2019; 114(3): 195-206.
3. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: A nested case-control study. Crit Care Med., 2010; 38(3): 771-778.
4. Christensen RD, Henry E, Wiedmeier SE, et al. The erythropoietin "brake" for preventing red blood cell transfusion in preterm infants: A randomized, placebo-controlled trial. J Pediatr, 2013; 163(6): 1592-1599.
5. Nischalke HD, Zimmermann O, Berger C, et al. Prophylactic washed platelet concentrates reduce major hemorrhage and mortality in children with leukemia undergoing chemotherapy: Results of a randomized, double-blind, controlled trial. Ann Hematol, 2016; 95(3): 437-444.
6. Schneider SS, Farmer SL. Leukocyte reduction of blood components. Transfusion, 2011; 51(Suppl 4): 67S-73S.
7. Shander A, Rijhwani TS, Javidroozi M, et al. Controversies in transfusion medicine: "Should we routinely filter the blood products we transfuse?". Anesth Analg, 2015; 121(4): 930-944.
8. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma, 2003; 55(1): 39-44.
9. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue. J Clin Apher, 2016; 31(3): 149-162.
10. Lozano M, Cid J. Leukoreduction and red blood cell transfusion outcomes: Current evidence. Blood Transfus, 2017; 15(6): 505-512.
11. Makroo RN, Raina V, Kumar P, et al. Reducing the risk of alloimmunization and transfusion-related acute lung injury: Evidence-based approach. Transfus Med Rev., 2013; 27(3): 125-141.
12. Benjamin RJ, Braschler T, Weingand KW. Prevention of transfusion-associated graft-versus-host disease by universal leukoreduction. Transfus Med Rev., 2006; 20(3): 215-227.
13. Callum JL, Rizkallah J, Scales DC, et al. A randomized controlled trial of the effect of bedside leucoreduction on the incidence of transfusion-

related acute lung injury in critically ill patients. Transfusion, 2015; 55(7): 1488-1495.
14. Milligan KA, Al-Ismaili Z, Rizkallah J, et al. Association between leukoreduced blood transfusions and infection risk in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant, 2019; 25(3): 597-604.
15. Tinmouth A, Fergusson D, Yee IC, Hébert PC. Clinical consequences of red cell storage in the critically ill. Transfusion, 2006; 46(11): 2014-2027.
16. Cholette JM, Henrichs KF, Alfieris GM, Powers KS, Phipps R, Spinelli SL. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: Results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med., 2012; 13(3): 290-299.
17. Janatpour KA, Kalmin ND, Jensen HM, et al. Lack of effect of prestorage white blood cell reduction on development of transfusion-associated microchimerism. Transfusion, 2002; 42(1): 27-31.
18. Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet storage time after transfusion: A systematic review and meta-analysis. Blood Transfus, 2016; 14(3): 248-258.
19. Eikelboom JW, Cook RJ, Liu Y, Heddle NM. Duration of red cell storage before transfusion and in-hospital mortality. Am Heart J., 2010; 159(5): 737-743.
20. Raval JS, Waters JH, Seltsam A, Scharberg EA, Yazer MH. The clinical significance of leukoreduction: Current perspectives. Blood Transfus, 2017; 15(3): 191-200.
21. Tobian AA, Fuller AK, Uglik KM, et al. The impact of recipient plasma and/or platelet transfusions on TRALI in the blood transfusion recipient epidemiology in the United States study population. Transfusion, 2017; 57(12): 2998-3006.
22. Wang Y, Tang Y, Gao Y, Liu X, Gao C, Wang L. Impact of leukoreduction on bacterial contamination in blood components: A systematic review and meta-analysis. Transfus Med Rev., 2021; 35(2): 126-133.
23. Prim N, Brailsford SR, Zuckerman M, et al. Hepatitis B virus DNA during the incubation period in two cases of transfusion-acquired infection. Transfusion, 2000; 40(8): 950-953.
24. Tung JP, Faddy HM, Devenish-Meares P, et al. The effect of whole-blood storage on plasma levels of cytokines and soluble cytokine receptors. Vox Sang., 2007; 93(1): 45-51.
25. Zimring JC, Welniak LA, Semple JW, Ness PM, Slichter SJ, Spitalnik SL. Current problems and future directions of transfusion-induced alloimmunization: Summary of an NHLBI working group. Transfusion, 2011; 51(2): 435-441.
26. De Wit E, Best L, Davidson D, Sattar A, Boushey RP. Platelet transfusion practice in cardiac surgery: A retrospective, descriptive analysis. Vox Sang, 2018; 113(6): 586-593.
27. Davoren A, Curtis BR, Shulman IA, Mohrbacher AF, Bux J, Kwiatkowska BJ, McFarland JG, Aster RH. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion, 2003 May; 43(5): 641-5.